# Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

> **NCT03185988** · PHASE2 · UNKNOWN · sponsor: **Shen Lin** · enrollment: 100 (estimated)

## Conditions studied

- Targeted Therapy
- HER2
- Biliary Tract Cancer
- Esophageal Squamous Cell Carcinoma
- Colorectal Cancer

## Interventions

- **DRUG:** chemotherapy in combination with trastuzumab for arm1
- **DRUG:** chemotherapy in combination with trastuzumab for arm2
- **DRUG:** chemotherapy in combination with trastuzumab for arm3
- **DRUG:** chemotherapy in combination with trastuzumab for arm4

## Key facts

- **NCT ID:** NCT03185988
- **Lead sponsor:** Shen Lin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2021-07
- **Final completion:** 2021-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03185988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03185988, "Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03185988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*